-7 Common Mistakes to Avoid
Key words:MOOYAM OEM; FDA Labeling Requirements for Skincare; 7 Common Mistakes in Skincare FDA Labeling; Skincare Labeling Compliance; US Skincare OEM Labeling; 2026 FDA Cosmetic Labeling Rules;
Entering the U.S. skincare market requires strict adherence to FDA cosmetic labeling regulations (21 CFR Parts 701 & 740). For cross-border brands partnering with OEMs, labeling non-compliance is the top cause of product detainment, recalls, or fines in 2026. MOOYAM OEM specializes in FDA-compliant labeling for skincare products, integrating regulatory expertise into every step of OEM production—from formula finalization to packaging design. This blog outlines the 7 most prevalent FDA labeling mistakes and provides clear, actionable solutions to ensure your products meet U.S. market standards.
7 Common FDA Skincare Labeling Mistakes & How to Avoid Them
1. Inaccurate Ingredient List Labeling
Mistake: Using non-INCI names (e.g., “Natural Aloe Extract” instead ofAloe Barbadensis Leaf Juice), misordering ingredients (not by descending weight predominance), or mislabeling trace ingredients (<1% concentration). Many brands also omit fragrance/Flavor components or processing aids required by 21 CFR 701.3(a). FDA Regulation: Ingredients must be listed by their International Nomenclature of Cosmetic Ingredients (INCI) names; ingredients >1% are ordered by weight, and ingredients <1% can be listed in any order after the 1% threshold. MOOYAM OEM Solution: Our regulatory team verifies all ingredients against the FDA’s INCI dictionary and cross-references formula batch records to ensure 100% accuracy. We automatically flag and correct non-compliant ingredient names and structure the list per 21 CFR 701.3 standards for every product.
2. Misleading Product Identity Statements
Mistake: Using vague or drug-like claims in the product identity (e.g., “Acne Cure Cream” instead of “Acne-Prone Skin Cleansing Cream”). This misclassifies cosmetics as drugs, which require FDA approval (NDA) and violates 21 CFR 701.10(a). FDA Regulation: The identity statement must clearly describe the product’s nature/use (e.g., “Moisturizing Lotion,” “Facial Cleanser”) and cannot imply therapeutic or medicinal benefits. MOOYAM OEM Solution: We conduct a pre-launch claim review to distinguish cosmetic vs. drug claims. Our copywriting team drafts compliant identity statements that align with your brand positioning while adhering to FDA guidelines, avoiding costly reclassifications.
3. Incomplete Net Quantity of Contents Labeling
Mistake: Only listing metric units (e.g., “120 mL”) without the required U.S. customary (avoirdupois/liquid) units, or using non-standard formatting (e.g., “4oz” instead of “4 fl oz” for liquids). FDA Regulation: Solid/semisolid products use avoirdupois pounds/ounces; liquids use U.S. liquid measure. Both metric and U.S. units must be displayed (e.g., “120 mL (4 fl oz)”) per 21 CFR 701.13. MOOYAM OEM Solution: Our packaging design system automatically generates compliant net quantity statements, validating unit types for solid/liquid/viscous products and ensuring dual-unit labeling meets FDA size and placement rules.
4. Missing or Non-Compliant Warning Statements
Mistake: Omitting mandatory warnings for hazardous products (e.g., flammable aerosols, unsubstantiated safety ingredients) or using insufficient font size/contrast for warnings. Common oversights include the “safety not determined” warning for unsubstantiated ingredients (21 CFR 701.4(a)). FDA Regulation: Warnings must be prominent (font ≥1/16 inch/1.6mm), in English, and placed in a conspicuous location. Specific products (e.g., aerosols, products with untested color additives) require fixed warning wording. MOOYAM OEM Solution: We map formula ingredients to FDA’s mandatory warning triggers and embed compliant warning text into packaging designs. Our quality control team verifies font size, contrast, and placement to meet 21 CFR 740.1 requirements.
5. Incomplete Manufacturer/Distributor Information
Mistake: Omitting the “responsible party” name and address, or using a PO box instead of a physical address. For imported products, failing to label the U.S. distributor’s contact information is a common violation. FDA Regulation: The label must include the name and physical address of the manufacturer, packer, or distributor (21 CFR 701.12). Imported cosmetics must list the U.S. agent/distributor’s information for regulatory correspondence. MOOYAM OEM Solution: We maintain a database of compliant responsible party information and ensure imported products include U.S. distributor details. Our team verifies address formatting to meet FDA’s “readability and accessibility” standards.
6. Non-Compliant Label Legibility & Display
Mistake: Using font sizes <1/16 inch for required text, low contrast (e.g., light gray on white), or placing mandatory information on “hidden” panels (not the principal display panel, PDP). FDA Regulation: All required labeling (identity, net quantity, ingredients, warnings) must be on the PDP or information panel, with text that is “easily readable” under customary viewing conditions (21 CFR 701.10). MOOYAM OEM Solution: Our packaging designers use FDA-compliant font specifications and contrast checks. We map all mandatory information to the correct panels (PDP/information panel) and provide mockup reviews for brand approval before production.
7. Ignoring “Professional Use Only” Retail Label Rules
Mistake: Labeling products “For Professional Use Only” but omitting required retail labeling (ingredients, net quantity, warnings). FDA enforces full labeling requirements for all consumer-facing products, even if marketed for professional use. FDA Regulation: The “professional use only” designation does not exempt products from 21 CFR 701 labeling requirements when sold to consumers (including aestheticians and salons). MOOYAM OEM Solution: We clarify labeling requirements based on your distribution channel. For professional products sold to consumers, we ensure full FDA labeling compliance; for closed-loop professional-only distribution, we implement industry best practices to avoid misbranding risks.
MOOYAM OEM: Your FDA Labeling Compliance Partner in 2026
Navigating FDA skincare labeling rules is complex, but non-compliance is avoidable with expert OEM support. MOOYAM OEM integratesregulatory verification into every stage of your product’s lifecycle—from formula development to packaging production—ensuring your labels meet 2026 FDA standards and U.S. market requirements.
We adhere to GMP, ISO 22716, and FDA regulations, providing one-stop services: INCI ingredient validation, compliant copywriting, packaging design review, and pre-shipment labeling audits. With MOOYAM OEM, your cross-border brand can launch FDA-compliant skincare products confidently, minimizing regulatory risks and accelerating market entry.
